We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Panel of Research-Use-Only Mass-Spec Biomarker Tests Launched at AACC 2015

By LabMedica International staff writers
Posted on 12 Aug 2015
Print article
Over 50 research-use-only (RUO) mass-spectrometry based biomarker tests, to be offered as a laboratory service, were launched during the 2015 AACC Meeting & Clinical Lab Expo (July 26–30; Atlanta, GA, USA). The RUO tests are specifically designed for detection and quantification of key protein biomarkers in human serum or plasma and are available to pharmaceutical companies for clinical trials, researchers, and as companion diagnostics.

Nuclea Biotechnologies, Inc. (Pittsfield and Cambridge, MA, USA) highlighted this new service offering available in addition to services from their CLIA/CAP-certified clinical labs.

Companion diagnostics can facilitate development and approval of novel therapeutic drugs and are becoming necessary for successful outcome in many clinical trials. “With the advent of monoclonal antibody and other protein-based drugs, it has become crucial for researchers to access precise companion diagnostic assays for targeted proteins. Mass-spectrometry based tests can selectively detect and quantify protein drug targets at the sequence level,” said Dr. Mary F Lopez, COO and VP of Proteomics Discovery, Nuclea.

Nuclea’s first clinical service laboratory, in Pittsfield, MA (USA), offers an array of fully validated and reimbursable IHC and ELISA tests for various cancer-associated proteins in tissue and blood. Nuclea will launch a second, high-complexity CLIA lab in their Cambridge, MA (USA) facility in late 2015. In addition to IHC and ELISA tests, this lab will offer state-of-the-art mass-spectrometry based multiplexed assays for serum or plasma proteins associated with diabetes, metabolic syndrome, and obesity. “This new service offering is a direct result of our ability to recruit a renowned team of experts in mass spectrometry,” said Patrick Muraca, president and CEO, Nuclea, “We know that biomarkers play a key role in drug development and that there is a market for these services to support clinical research.”

Related Links:

Nuclea Biotechnologies
American Association for Clinical Chemistry (AACC)
AACC 2015 Annual Meeting & Clinical Lab Expo


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.